ReviewOpen veterinary journal2026
Ebola virus disease: A persistent challenge in global health security.
Review in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ebola virus disease (EVD) is a highly fatal zoonotic disease caused by a negative-stranded RNA virus of the genus Ebolavirus in the family Filoviridae. Since its first discovery in 1976 in Central Africa, the disease has triggered several large outbreaks with a mortality rate that can reach 90%. Ebola is transmitted through direct contact with the blood, body fluids, or tissues of infected individuals, including corpses, and can also spread in healthcare facilities if infection control procedures are not properly implemented. Fruit bats of the family Pteropodidae are thought to be the natural reservoir of the virus, playing a role in maintaining the ecological cycle and facilitating zoonotic transmission to humans through intermediary animals such as non-human primates. Clinically, EVD typically begins with high fever, muscle pain, vomiting, diarrhea, and extensive bleeding that can progress to multiple organ failure. Barriers to early detection, limited diagnostic laboratories, and weak health system preparedness in endemic areas contribute to accelerating the spread of the disease. The major outbreak that occurred in West Africa in 2014-2016 provided a crucial momentum for improving the global health system, particularly in terms of surveillance, rapid detection, and coordination between countries. Current EVD prevention and control efforts focus on a One Health approach, the implementation of stringent biosafety standards, the use of the rVSV-ZEBOV vaccine, and the development of monoclonal antibody-based antiviral therapies. This review reviews the latest developments in EVD pathogenesis, epidemiology, and mitigation strategies to strengthen preparedness for potential future outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.